提问
问诊
发现
计算
注册
注册
登录
登录
发现
FDA Fast Track Designation Granted to Ozuriftamab Vedotin for Recurrent or Metastatic SCCHN After Platinum and Anti-PD-1/L1 Therapy - Vera Health News